Chen En-Guo, Zhang Ji-Song, Xu Shan, Zhu Xiao-Jing, Hu Hui-Hui
Department of Pulmonary Medicine, Sir Run Run Shaw Hospital of Zhejiang UniversityHangzhou 310016, Zhejiang Province, China.
Am J Cancer Res. 2017 Jul 1;7(7):1463-1475. eCollection 2017.
Accumulating studies have demonstrated that non-coding RNAs (ncRNAs), including small non-coding RNAs (small ncRNAs) and long non-coding RNAs (lncRNAs), are involved in tumor growth in lung cancer (LC). However, the specific role of DGCR5 in LC progression is not yet clear. In the present study, we found that DGCR5 was downregulated and miR-1180 was upregulated in the sera and tissues of LC patients and was correlated with poor prognosis. We also found that DGCR5 suppressed proliferation, migration and invasion of LC cell lines H520 and H1299. In addition, a luciferase reporter gene assay was used to investigate the regulatory relationship between DGCR5 and miR-1180. Furthermore, we suggested that DGCR5 inhibited the expression of AKT, GSK-3β, and β-catenin by targeting miR-1180. Based on these findings, DGCR5 might serve as a potential target for the development of effective anti-neoplastic therapies in lung cancer.
越来越多的研究表明，非编码RNA（ncRNAs），包括小非编码RNA（小ncRNAs）和长非编码RNA（lncRNAs），参与肺癌（LC）的肿瘤生长。然而，DGCR5在LC进展中的具体作用尚不清楚。在本研究中，我们发现LC患者的血清和组织中DGCR5表达下调，miR-1180表达上调，且与预后不良相关。我们还发现DGCR5抑制LC细胞系H520和H1299的增殖、迁移和侵袭。此外，采用荧光素酶报告基因实验研究DGCR5与miR-1180之间的调控关系。此外，我们认为DGCR5通过靶向miR-1180抑制AKT、GSK-3β和β-连环蛋白的表达。基于这些发现，DGCR5可能成为开发有效的肺癌抗肿瘤治疗方法的潜在靶点。
